Checkpoint Inhibition for Kidney Transplant Recipients With Advanced Cutaneous Carcinomas: An Emerging Standard for Select Patients
Cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers overall in the United States with over one million patients diagnosed annually. While most CSCCs are highly curable with surgery alone, 5%-10% of patients experience disease recurrence and death, which amounts to mortality rates exceeding those of melanoma. 1 One of the highest-risk populations with CSCC that experience poor outcomes is the immune suppressed population. First, immune-compromised patients are at up to a 250-fold